药物性肝损伤患者外周血淋巴细胞谱和免疫检查点受体及其配体表达变化分析*

doi:10.3969/j.issn.1672-5069.2024.03.016

摘要/Abstract

摘要： 目的分析药物性肝损伤(DILI)患者外周血淋巴细胞谱和免疫检查点受体及其配体表达变化。方法 2020年3月～2023年3月我院诊治的DILI患者62例、自身免疫性肝炎(AIH)患者35例和非酒精性脂肪性肝病(NAFLD)患者40例,使用流式细胞仪检测外周血淋巴细胞谱和免疫检查点受体及其配体表达。结果 DILI组外周血活化Th细胞百分比为(14.2±3.8)%,显著高于AIH组【(9.7±2.3)%,P<0.05】或NAFLD组【(8.2±2.7)%,P<0.05】,DILI组和AIH组外周血活化TC细胞百分比分别为(31.3±9.2)%和(32.2±7.7)%,显著高于NAFLD组【(22.6±5.9)%,P<0.05】,Th9细胞百分比分别为(19.7±3.3)%和(19.2±2.8)%,显著低于NAFLD组【(25.3±5.4)%,P<0.05】,DILI组和NAFLD组外周血Th1细胞百分比分别为(52.6±12.3)%和(53.2±11.8),显著高于AIH组【(43.4±10.7)%,P<0.05】;DILI组外周血ICOS表达阳性Th细胞百分比为(5.2±1.5)%,显著高于AIH组【(3.9±1.1)%,P<0.05】或NAFLD组【(1.9±0.8),P<0.05】,而AIH组CTLA-4和PD-1表达阳性Th细胞百分比分别为(37.4±5.1)%和(15.7±2.3)%,显著高于DILI组【分别为(28.3±3.4)%和(12.8±1.9)%,P<0.05】或NAFLD组【分别为(18.2±3.2)%和(10.2±1.6)%,P<0.05】。结论在DILI发病的进展期间,活化的T淋巴细胞占比增加,可能参与了适应性免疫反应发病过程。了解这些现象,对阐明DILI潜在的发病机制研究可能有帮助。

关键词: 药物性肝损伤, 淋巴细胞谱, 免疫检查点

Abstract: Objective The aim of this study was to investigate peripheral blood lymphocyte spectrum and immune checkpoint receptors and their ligand expression in patients with drug-induced liver injury (DILI). Methods 62 patients with DILI, 35 patients with autoimmune hepatitis (AIH) and 40 patients with nonalcoholic fatty liver disease (NAFLD) were recruited in our hospital between March 2020 and March 2023, and peripheral blood lymphocyte spectrum and immune checkpoints receptors and their ligand expression were detected by FCM. Results The percentage of peripheral blood activated Th cells in patients with DILI was (14.2±3.8)%, significantly higher than [(9.7±2.3)%, P<0.05] in patients with AIH or [(8.2±2.7)%, P<0.05] in patients with NAFLD, the percentage of peripheral blood activated TC cells in patients with DILI and AIH were (31.3±9.2)% and (32.2±7.7)%, significantly higher than [(22.6±5.9)%, P<0.05] in patients with NAFLD, while the percentages of Th9 cells were (19.7±3.3)% and (19.2±2.8)%, much lower than [(25.3±5.4)%, P<0.05] in patients with NAFLD, and the percentages of Th1 cells in patients with DILI and NAFLD were (52.6±12.3)% and (53.2±11.8), much higher than [(43.4±10.7)%, P<0.05] in patients with AIH; the percentage of Th cells with ICOS expression positive in patients with DILI was (5.2±1.5)%, much higher than [(3.9±1.1)%, P<0.05] in patients with AIH or [(1.9±0.8), P<0.05] in patients with NAFLD, while the percentages of Th cells with CTLA-4 and PD-1 expression positive in patients with AIH were (37.4±5.1)% and (15.7±2.3)%, much higher than [(28.3±3.4)% and (12.8±1.9)%, respectively, P<0.05] in patients with DILI or [(18.2±3.2)% and (10.2±1.6)%, respectively, P<0.05] in those with NAFLD. Conclusion During the progress of DILI, the number of peripheral blood activated T lymphocytes increases, which might participate in the pathogenesis of this entity, and needs further investigation.

Key words: Drug induced liver injury, Lymphocyte spectrum, Immune checkpoint

郎平, 崔闪闪, 赵艳. 药物性肝损伤患者外周血淋巴细胞谱和免疫检查点受体及其配体表达变化分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 382-385.

Lang Ping, Cui Shanshan, Zhao Yan. Peripheral blood lymphocyte spectrum and immune checkpoint receptor and their ligand expression in patients with drug-induced liver injury[J]. Journal of Practical Hepatology, 2024, 27(3): 382-385.

参考文献

[1] 李玉红, 郝明媛, 焦连丽, 等. 基于细胞焦亡理论研究白细胞介素-1β与白细胞介素-18在抗结核药物性肝损伤中的临床意义. 中国医科大学学报, 2020, 49(5): 396-399,e404.
[2] 曾潇, 韦鸿雁, 廖金卯, 等. 不同类别药物致急性药物性肝损伤的临床特征比较及严重程度影响因素分析. 中国医院药学杂志, 2022, 42(3): 313-317.
[3] Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Modern Pathol, 2018, 31(6): 965-973.
[4] Weaver RJ, Blomme EA, Chadwick AE, et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov, 2020, 19(2): 131-148.
[5] 潘韵铮, 胡洋, 李庆菊, 等. 特异质型药物性肝损伤发生机制及其评价方法的研究进展. 中国药理学与毒理学杂志, 2020, 34(12): 946-953.
[6] 中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等.药物性肝损伤基层诊疗指南(2019年). 中华全科医师杂志, 2020, 19(10): 868-875.
[7] Albrecht W, Kappenberg F, Brecklinghaus T, et al. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations. Arch Toxicol, 2019, 93(6): 1609-1637.
[8] Jiao X, Xiao Y, Li Y, et al. Evaluating drug-induced liver injury and its remission via discrimination and imaging of HClO and H2S with a two-photon fluorescent probe. Anal Chem, 2018, 90(12): 7510-7516.
[9] Nicoletti P, Aithal G P, Chamberlain T C, et al. Drug-induced liver injury due to flucloxacillin: relevance of multiple human leukocyte antigen alleles. Clin Pharmacol Ther, 2019, 106(1): 245-253.
[10] Mack C L, Adams D, Assis D N, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology, 2020, 72(2): 671-722.
[11] Benesic A, Rotter I, Dragoi D, et al. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin Gastroenterol H, 2018, 16(9): 1488-1494.
[12] Hegde P, Weiss E, Paradis V, et al. Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nat Commun, 2018, 9(1): 1-12.
[13] Cueto-Sanchez A, Niu H, Del Campo-Herrera E, et al. Lymphocyte profile and immune checkpoint expression in drug-Induced liver injury: An immunophenotyping study. Clin Pharmacol Ther, 2021, 110(6): 1604-1612.
[14] Mak A, Cho T, Uetrecht J. Use of an animal model to test whether non-alcoholic fatty liver disease increases the risk of idiosyncratic drug-induced liver injury. J Immunotoxicol, 2018, 15(1): 90-95.
[15] Cho T, Wang X, Yeung K, et al. Liver injury caused by green tea extract in Pd-1–/–mice: an impaired immune tolerance model for idiosyncratic drug-induced liver injury. Chem Res Toxicol, 2021, 34(3): 849-856.
[16] Guo X, Li W, Hu J, et al. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. Eur J Clin Pharmacol, 2020, 76(10): 1345-1354.
[17] Devarbhavi H, Patil M, Reddy V V, et al. Drug-induced acute liver failure in children and adults: Results of a single-centre study of 128 patients. Liver Int, 2018, 38(7): 1322-1329.
[18] Church R J, Kullak-Ublick G A, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: an international collaborative effort. Hepatology, 2019, 69(2): 760-773.
[19] 胡亚秋, 汪妮, 冉锡萍, 等. 评估免疫检查点抑制剂为基础的联合治疗在原发性肝癌患者中肝损伤发生情况的真实世界研究. 中华肝脏病杂志, 2022, 30(1): 57-62.
[20] Zhang L, Niu M, Wei A, et al. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum. Arch Toxicol, 2020, 94(1): 245-256.

药物性肝损伤患者外周血淋巴细胞谱和免疫检查点受体及其配体表达变化分析^*

Peripheral blood lymphocyte spectrum and immune checkpoint receptor and their ligand expression in patients with drug-induced liver injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	梁丹丹, 江建宁, 黄锦妮, 龙诗雨, 董国珍, 苏曼, 李继娇, 滕春玲, 张萍, 苏明华. 219例药物性肝损伤患者临床特征和预后分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 210-213.
[2]	张天祺, 王敏, 杨娜, 朱怀军. 应用替加环素治疗重症感染患者DILI发生及其影响因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 214-217.
[3]	任浩, 刘力伟, 施维, 刘波, 吴于青, 吕芹. 苦黄注射液预防抗结核药物导致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 56-59.
[4]	杨开宁, 王梦梦, 王占坤, 陈秀秀, 肖剑, 王永丽. 注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 839-842.
[5]	于双杰, 李元元, 毕京峰, 福军亮, 宓余强. ICIs联合TKIs治疗HBV相关肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 891-894.
[6]	李玲, 何小琪, 高勇, 方春田, 盛天驰, 王燕, 郑红梅. 孕期药物性肝损伤患者血清miR-21、Nrf2和HO-1水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 662-665.
[7]	莫俊俏, 林景, 羊莉. 水飞蓟宾胶囊联合多烯磷脂酰胆碱治疗抗结核药物所致药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 666-669.
[8]	裴素娟, 郭锦辉, 魏晓霞. 综合医院住院患者药物性肝损伤发生致病药物及影响肝损伤严重程度的因素分析^*[J]. 实用肝脏病杂志, 2023, 26(5): 670-673.
[9]	桂芬芬, 周杰斌. MicroRNAs作为药物性肝损伤生物标记物研究进展[J]. 实用肝脏病杂志, 2023, 26(5): 761-764.
[10]	符馨尹, 林小茹, 郑秀芬, 刘小双. 药物诱导性自身免疫性肝炎与药物性肝损伤和自身免疫性肝炎患者临床特征比较研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 512-515.
[11]	唐新华, 唐慧京, 黄成军, 李观. 恩替卡韦治疗血清HBeAg阳性高病毒载量乙型肝炎病毒携带者合并肺结核患者预防抗痨治疗引起的药物性肝损伤效果研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 516-519.
[12]	王俊红, 戴玲, 陈国斌, 杨路平, 周晶. 还原型谷胱甘肽、甘草酸二铵和复方甘草酸苷治疗抗结核药物所致药物性肝损伤患者成本-效益分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 380-383.
[13]	杨开宁, 王梦梦, 陈秀秀, 王占坤, 董紫薇. 不同护肝药物护佑抗痨治疗防治药物性肝损伤发生研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 384-387.
[14]	卫栋萍, 韩黎黎, 凌佳慧, 顾晓琴, 曹永峰. 甘草酸二胺与复方甘草酸苷治疗环磷酰胺所致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 388-391.
[15]	陈鹏, 刘欢, 徐亮. 免疫检查点抑制剂治疗晚期肝细胞癌患者研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 453-456.